GlassScriptPhysician profile
Nicholas E Vogelsang
NPI 1184939035
$17,675.36
in general payments reported to CMS, 2019-2025
39 companies · $536 in 2025
The $536 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,158 · 2020: $1,012 · 2021: $6,575 · 2022: $196 · 2023: $424 · 2024: $1,775 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,142 · Education: $594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,141.53 |
| Education | $593.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dne LLC | $5,000.00 | 2019 | |
| Triad Life Sciences INC. | $4,500.00 | 2021 | |
| Misonix INC | $1,888.13 | 2020-2021 | |
| Smith+Nephew, INC. | $1,048.97 | 2019-2023 | Cadence |
| Integra Lifesciences Corporation | $978.32 | 2019-2022 | |
| Stryker Corporation | $894.74 | 2019-2024 | Easyfuse, Ortholoc 3di, Variax |
| Carbofix Orthopedics INC | $593.54 | 2024 | Mtp Plate |
| Treace Medical Concepts, INC. | $398.88 | 2024-2025 | |
| Epsfl, LLC | $275.43 | 2023 | |
| Nevro Corp. | $250.13 | 2023-2024 | Senza |
| Acera Surgical, INC. | $203.55 | 2019-2021 | |
| Organogenesis INC. | $189.38 | 2019-2024 | |
| Mimedx Group, INC. | $160.41 | 2024 | |
| Arteriocyte Medical Systems, INC. | $153.06 | 2024 | Magellan |
| Fusion Orthopedics USA, LLC | $115.14 | 2024-2025 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Vogelsang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.